Retatrutide

Retatrutide (LY3437943) is an investigational peptide that acts as a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its multi-receptor activity makes it a subject of ongoing research into metabolic signaling and related biological pathways. The 10 mg presentation is intended for qualified research environments investigating receptor activity, metabolic pathways, and peptide biology. The compound is supplied for controlled laboratory research and should be evaluated according to appropriate institutional protocols and applicable regulations.

Key Features

10 mg research-grade peptide Investigational GIP, GLP-1, and glucagon receptor agonist Suitable for in-vitro and preclinical research applications Relevant to metabolic and endocrine signaling research Intended for controlled laboratory environments Batch documentation and analytical verification should accompany the applicable product lot Research Focus Retatrutide has been studied extensively in clinical research as a multi-receptor peptide, with investigations examining metabolic and endocrine pathways. Its activity across three receptor systems makes it a notable candidate for ongoing scientific research.

Important Notice

This product is supplied strictly for research and laboratory use. Retatrutide remains an investigational molecule and has not been approved for general public use. It is not intended for human or veterinary use, consumption, diagnosis, treatment, or prevention of disease.